Aya Mohamed, Breast CA Specialist and Researcher, shared on X:
“BFv, a Nectin-4–targeted ADC, showed activity in pretreated mTNBC after prior Top1i-ADC exposure (ORR 30%).
The key question is whether this activity translates into durable benefit and a meaningful option after ADC progression.”
Conclusion։
- BFv demonstrated promising antitumor activity with a manageable safety profile in heavily pretreated patients with la/mTNBC who had all received prior Top1i-based ADCs.
- The first pivotal trial for this indication worldwide is underway.
Safety and Efficacy results are shown below.
You can also read: OptiTROP-Breast01 Final Analysis: Sacituzumab Tirumotecan Sustains Overall Survival Benefit in Previously Treated Metastatic Triple-Negative Breast Cancer
